Hamdi Nsairat, Omer Qutaiba B Allela, Abdulkareem Shareef, S Renuka Jyothi, Priya Priyadarshini Nayak, Ashish Singh Chauhan, Hayder Naji Sameer, Ahmed Yaseen, Zainab H Athab, Mohaned Adil
{"title":"Aptamer biosensors in early breast cancer detection.","authors":"Hamdi Nsairat, Omer Qutaiba B Allela, Abdulkareem Shareef, S Renuka Jyothi, Priya Priyadarshini Nayak, Ashish Singh Chauhan, Hayder Naji Sameer, Ahmed Yaseen, Zainab H Athab, Mohaned Adil","doi":"10.1016/j.cca.2025.120536","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer, a leading cause of cancer-related mortality among women, necessitates the development of sensitive and specific diagnostic tools for early detection and personalized treatment. An aptamer-based biosensor (aptasensor) is a biosensor that utilizes aptamers as its biorecognition element such as single-stranded DNA or RNA molecules that are specifically selected to bind to a target molecule with high affinity. Aptasensors have emerged as promising alternatives to traditional methods, offering advantages such as high affinity, specificity, and ease of synthesis. This review provides an overview of recent advancements in aptasensor technology for breast cancer diagnostics, focusing on the detection of key biomarkers. In this review, first after an overview to different types of aptasensors, we discuss the different type of aptamer immobilization methods on sensor surfaces using covalent, adsorption, and thiol-based self-assembly techniques. Furthermore, we present different aptasensor platforms, including electrochemical and optical approaches, highlighting their design principles, performance characteristics, and clinical applications.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120536"},"PeriodicalIF":2.9000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cca.2025.120536","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Breast cancer, a leading cause of cancer-related mortality among women, necessitates the development of sensitive and specific diagnostic tools for early detection and personalized treatment. An aptamer-based biosensor (aptasensor) is a biosensor that utilizes aptamers as its biorecognition element such as single-stranded DNA or RNA molecules that are specifically selected to bind to a target molecule with high affinity. Aptasensors have emerged as promising alternatives to traditional methods, offering advantages such as high affinity, specificity, and ease of synthesis. This review provides an overview of recent advancements in aptasensor technology for breast cancer diagnostics, focusing on the detection of key biomarkers. In this review, first after an overview to different types of aptasensors, we discuss the different type of aptamer immobilization methods on sensor surfaces using covalent, adsorption, and thiol-based self-assembly techniques. Furthermore, we present different aptasensor platforms, including electrochemical and optical approaches, highlighting their design principles, performance characteristics, and clinical applications.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.